8 completed, 5 terminated, 2 unknown. 15 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 8, Terminated 5, Unknown 2 |
| Phase 1 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow lorcaserin: new trials by email Literature Review of lorcaserin trials Research Report on lorcaserin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mechanisms of Lorcaserin for Smoking Cessation Lorcaserin Oral Tablet, Placebo oral tablet - Tobacco Use Disorder, Smoking Cessation | Phase 2 | Terminated | The Mind Research Network | 3 | 2019-12-04 | 2023-03-20 |
| Laboratory Screening of Lorcaserin for Alcohol Use Disorder Lorcaserin Oral Tablet, Placebo oral tablet - Alcohol Use Disorder, Tobacco Smoking | Phase 2 | Terminated | The Mind Research Network | 5 | 2019-10-25 | 2022-09-07 |
| Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Duloxetine 60 mg qd, Lorcaserin - Chemotherapy-Induced Peripheral Neuropathy | Phase 2 | Unknown | Southeastern Regional Medical Center | 50 | 2019-06-01 | 2019-04-04 |
| Treatment With Lorcaserin for Cocaine Use: The TLC Study lorcaserin, Placebo Oral Tablet, Substance use counseling - Cocaine Use Disorder | Phase 2 | Terminated | Glenn-Milo Santos | 22 | 2018-01-01 | 2023-08-14 |
| Lorcaserin in the Treatment of Cocaine Use Disorder Lorcaserin, Placebo Oral Capsule - Cocaine-Related Disorders | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 272 | 2017-12-19 | 2020-08-05 |
| Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Lorcaserin, Placebo, Marijuana - Cannabis Use | Phase 1 / Phase 2 | Completed | New York State Psychiatric Institute | 15 | 2017-09-05 | 2022-07-26 |
| Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder Lorcaserin, Placebo - Opioid-use Disorder | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 60 | 2017-05-25 | 2020-10-05 |
| Combination Nicotine Patch / Lorcaserin for Smoking Cessation lorcaserin, nicotine patch, placebo lorcaserin - Nicotine Dependence | Phase 2 | Completed | Duke University | 97 | 2016-11-08 | 2019-05-07 |
| Addressing Post Cessation Weight Gain lorcaserin, Varenicline, Placebo - Obesity, Smoking Cessation | Phase 2 / Phase 3 | Terminated | Mayo Clinic | 84 | 2016-06-15 | 2021-06-10 |
| Evaluating Muscle Weakness Improvement With Lorcaserin in ICU Lorcaserin, Placebo - Muscle Weakness, Sepsis | Phase 1 / Phase 2 | Terminated | Johns Hopkins University | 5 | 2015-12-01 | 2020-01-13 |
| Lorcaserin Intra Venous Cocaine Effects Lorcaserin, 10 mg, Lorcaserin, 20 mg, Oral Placebo - Cocaine Use Disorders | Phase 1 / Phase 2 | Unknown | Midwest Biomedical Research | 32 | 2015-11-01 | 2016-03-18 |
| A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation APD356-lorcaserin hydrochloride, Placebo - Smoking Cessation | Phase 2 | Completed | Arena Pharmaceuticals | 603 | 2014-03-01 | 2019-04-16 |
| Lorcaserin for Preventing Weight Gain Among Smokers Varenicline, Lorcaserin - Tobacco Use Disorder, Weight Gain | Phase 1 / Phase 2 | Completed | Mayo Clinic | 20 | 2013-09-01 | 2017-06-06 |
| Safety and Efficacy of APD356 in the Treatment of Obesity APD356 - Obesity | Phase 2 | Completed | Eisai Inc. | 400 | 2005-06-01 | 2019-09-12 |
| Safety and Efficacy of APD356 in the Treatment of Obesity APD356 - Obesity | Phase 2 | Completed | Eisai Inc. | 400 | 2004-12-01 | 2019-09-12 |
Obesity (4) · Smoking Cessation (4) · Tobacco Use Disorder (3) · Anorexia (2) · Overweight (2) · Weight Loss (2) · Alcoholism (1) · Cigarette Smoking (1) · Cocaine-Related Disorders (1) · Muscle Weakness (1) · Opioid-Related Disorders (1) · Sepsis (1) · Sexual Behavior (1) · Tobacco Smoking (1) · Weight Gain (1)
Eisai Inc. (2) · Mayo Clinic (2) · New York State Psychiatric Institute (2) · The Mind Research Network (2) · Arena Pharmaceuticals (1) · Duke University (1) · Glenn-Milo Santos (1) · Johns Hopkins University (1) · Midwest Biomedical Research (1) · National Institute on Drug Abuse (NIDA) (1) · Southeastern Regional Medical Center (1)
United States (15)
Christian Hendershot, Ph.D. (2) · Eric Claus, Ph.D. (2) · Dale M Needham, MD, PhD (1) · Donald Anderson, M.D. (1) · Frances R Levin, MD (1) · Glenn-Milo Santos, PhD, MPH (1) · Jed E. Rose, Ph.D. (1) · Kenneth W Grasing, MD (1) · Ryan Hurt, MD, PhD (1) · Ryan T Hurt, MD, PhD (1) · Shwe Gyaw, MD (1)
PMID 34611902, PMID 19057523, PMID 27815511, PMID 27852796, PMID 30811963, PMID 31589323, PMID 34265007, PMID 36160639
K23DA037299 (1), P50DA027840 (1), R34DA042161 (1), UL1TR001079 (1)